4.7 Article

Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19 An Analysis From Get With The Guidelines-Stroke

期刊

STROKE
卷 52, 期 10, 页码 3225-3232

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.120.034414

关键词

coronavirus; inpatient; ischemic stroke; pandemics; tomography

资金

  1. Genentech
  2. American Heart Association/American Stroke Association
  3. Novartis
  4. Boehringer Ingelheim
  5. Eli Lilly Diabetes Alliance
  6. Novo Nordisk
  7. Sanofi
  8. AstraZeneca
  9. Bayer
  10. Portola Pharmaceuticals
  11. Inc-A Member of the Roche Group

向作者/读者索取更多资源

This study analyzed the characteristics, treatment, and outcomes of acute ischemic stroke patients before and during the COVID-19 pandemic. While stroke presentations decreased during COVID-19, the treatment and in-hospital outcomes remained similar to pre-COVID-19 levels.
Background and Purpose: The coronavirus disease 2019 (COVID-19) pandemic has created challenges in the delivery of acute stroke care. In this study, we analyze the characteristics, evaluation, treatment, and in-hospital outcomes of patients presenting with acute ischemic stroke (AIS) pre-COVID-19 and during COVID-19. Methods: Get With The Guidelines-Stroke is a national registry of adults with stroke in the United States. Using this registry, we identified patients with a diagnosis of AIS before (n=39 113; November 1, 2019-February 3, 2020) and after (n=41 971; February 4, 2020-June 29, 2020) the first reported case of COVID-19 in the registry. Characteristics, treatment patterns, quality metrics, and in-hospital outcomes were compared between the 2 groups. Results: Stroke presentations decreased by an average of 15.3% per week in the during COVID-19 time period when compared with similar months in 2019. Compared with patients with AIS in the pre-COVID-19 era, patients in the COVID-19 time period had similar rates of intravenous alteplase and endovascular therapy, and similar door to computed tomography, door to needle, and door to endovascular therapy times. In adjusted models, inpatient mortality was similar between those presenting with AIS pre-COVID-19 and during COVID-19 (4.8% versus 5.2%; odds ratio, 1.05 [95% CI, 0.97-1.13]). Conclusions: Among hospitals participating in Get With The Guidelines-Stroke, patients presenting with AIS during COVID-19 received, with few exceptions, similar quality care and experienced similar risk-adjusted outcomes when compared with patients with AIS presenting pre-COVID-19. These findings demonstrate that stroke care in the United States remains robust during the COVID-19 pandemic.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据